NASDAQ$INKT
Mink Therapeutics Inc · Q4 2026 earnings
Q4 2026 earnings · · Before market open · Investor relations
Briefing
MiNK Therapeutics reported a net loss of $2.7 million for the first quarter of 2026 with continued progress on its iNKT cell therapy pipeline.
MiNK Therapeutics, a clinical-stage biotech developing allogeneic iNKT cell therapies, posted a Q1 2026 net loss of $2.74 million compared to $2.77 million in the prior-year quarter. Operating expenses totaled $2.88 million, driven by R&D and G&A activities supporting ongoing clinical trials in oncology, pulmonary diseases, and GvHD. The company ended the quarter with $9.5 million in cash and subsequently raised additional funds via ATM sales while repaying its related-party note.
- Net loss narrowed slightly to $2.74 million from $2.77 million year-over-year as R&D expenses declined 5%.
- Cash position stood at $9.53 million at quarter-end after repaying the $5 million Agenus note and raising $3.0 million via ATM equity sales.
- Clinical momentum continued with Phase 2 trials advancing for agenT-797 in severe pneumonia and gastroesophageal cancers plus new GvHD prevention study.
- Preclinical progress on engineered candidates MiNK-215 and MiNK-413 supported by manufacturing and translational data updates.
Headline financials
Revenue & EPS history
Mink Therapeutics · Revenue · Quarterly
$0
Forward guidance
Company expects to require additional funding to advance clinical programs and maintain operations beyond the next twelve months.
Tailwinds
- Substantial doubt about going concern disclosed but mitigated by anticipated funding sources
- Multiple clinical data readouts expected in second half of 2026
Headwinds
- Continued operating losses and negative cash flows projected
- Additional capital raises likely to be dilutive
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2026
-3.6%
Avg return
Earnings day
-4.9%
Avg return
5 days after
-1.7%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+14.6%
Q3 2022
Best reaction
-42.0%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +3.9% | +2.2% | +13.3% | |
| Q3 2025 | -1.9% | -16.6% | -6.1% | |
| Q2 2025 | -13.6% | -16.0% | -17.7% | |
| Q1 2025 | -3.3% | -3.8% | -3.3% | |
| Q4 2024 | -3.3% | +6.8% | -14.9% | |
| Q3 2024 | -5.0% | -13.5% | -22.4% | |
| Q2 2024 | +0.6% | -3.0% | -8.5% | |
| Q1 2024 | +6.1% | +3.1% | -1.4% | |
| Q4 2023 | -2.9% | +4.7% | -2.2% | |
| Q3 2023 | -11.8% | -20.2% | -14.3% | |
| Q2 2023 | +1.7% | -5.0% | -26.1% | |
| Q1 2023 | +13.9% | +11.3% | +44.4% | |
| Q4 2022 | +0.5% | -3.4% | -3.4% | |
| Q3 2022 | +14.6% | +17.8% | +18.3% | |
| Q2 2022 | +13.2% | +25.7% | +114.7% | |
| Q1 2022 | -26.7% | -26.7% | -13.1% | |
| Q4 2021 | -6.1% | -4.2% | -5.5% | |
| Q3 2021 | -6.1% | -4.2% | -5.5% | |
| Q2 2021 | -42.0% | -47.6% | -78.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro